scholarly journals Adherence in adults with type 1 diabetes mellitus correlates with treatment satisfaction but not with adverse events

2013 ◽  
pp. 867 ◽  
Author(s):  
Tereza Hendrychova ◽  
Magda Vytrisalova ◽  
Smahelova ◽  
Jiri Vlcek ◽  
Kubena
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Adverse Events ◽  
Type 1 Diabetes Mellitus ◽  
Treatment Satisfaction

scholarly journals PDB96 THE IMPACT OF ADJUNCT DAPAGLIFLOZIN ON TREATMENT SATISFACTION IN TYPE 1 DIABETES MELLITUS

2019 ◽  
Vol 22 ◽  
pp. S590
Author(s):  
J. Gordon ◽  
L. Beresford-Hulme ◽  
H. Bennett ◽  
A. Tank ◽  
C. Edmonds ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Treatment Satisfaction ◽  
The Impact

Unforeseen consequences of cancer immunotherapy

2018 ◽  
Vol 3 (1) ◽  
pp. 20
Author(s):  
Radhika Vaishnav ◽  
Wakas Arslan ◽  
Divyesh G. Mehta
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Side Effects ◽  
Adverse Events ◽  
Type 1 Diabetes Mellitus ◽  
Cancer Progression ◽  
Fast Moving ◽  
Clinical Presentation ◽  
New Treatments

<p>With the increasing use of immunotherapy for various cancers, it is essential that clinicians become aware of some of the unique consequences and sude effects associated with these new treatments. Ranging from pneumonitis and colitis to Type 1 Diabetes Mellitus, immune related adverse events have been reported. Some side effects may be confused with cancer progression and thus awareness and clinical presentation of these is critical and necessary in this fast moving field of medicine.</p>

scholarly journals Diabetes mellitus secondary to treatment with immune checkpoint inhibitors

2019 ◽  
Vol 26 (1) ◽  
Author(s):  
V. Venetsanaki ◽  
A. Boutis ◽  
A. Chrisoulidou ◽  
P. Papakotoulas
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Adverse Events ◽  
Type 1 Diabetes Mellitus ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Positive Outcome ◽  
Develop Type

Cancer immunotherapy has been one of the highlights in the advancement of cancer care. Certain immune checkpoint inhibitors bind to PD-1 on T cells and mediate an antitumour immune response. Given that immune checkpoint inhibitors are becoming part of standard care, a new class of adverse events—immune-related adverse events—has emerged.  Among them is endocrine toxicity, most commonly targeting the thyroid, pituitary, or adrenal glands. New-onset diabetes mellitus has been reported in fewer than 1% of patients. We present a patient with type 1 diabetes mellitus secondary to immunotherapy, together with an overview of the associated literature. Patients who develop type 1 diabetes mellitus experience a rapid course, and diabetic ketoacidosis is commonly the presenting symptom. Insulin is currently the treatment of choice; oral antidiabetics or corticosteroids do not assist in management. Several predictive factors are under investigation, but physician awareness and prompt management are key to a positive outcome.

Cutaneous adverse events in a randomized controlled trial of flash glucose monitoring among youth with type 1 diabetes mellitus

2020 ◽  
Vol 21 (8) ◽  
pp. 1516-1524
Author(s):  
Brooke L. Marsters ◽  
Sara E. Boucher ◽  
Barbara C. Galland ◽  
Esko J. Wiltshire ◽  
Martin I. Bock ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Randomized Controlled Trial ◽  
Type 1 Diabetes ◽  
Adverse Events ◽  
Type 1 Diabetes Mellitus ◽  
Controlled Trial ◽  
Glucose Monitoring ◽  
Flash Glucose Monitoring ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document